Teduglutide CAS:197922-42-2

Teduglutide serves several important therapeutic purposes related to gastrointestinal health and management of short bowel syndrome: Promoting Intestinal Adaptation: Teduglutide stimulates intestinal growth and enhances the absorption capacity of the remaining bowel segments, reducing dependence on parenteral nutrition (intravenous feeding). Reducing Parenteral Nutrition Dependency: By increasing intestinal absorption, Teduglutide helps decrease the need for parenteral nutrition, improving patients' quality of life and reducing complications associated with its long-term use. Improving Fluid and Nutrient Absorption: It enhances fluid and nutrient absorption in the intestine, addressing the malabsorption issues characteristic of short bowel syndrome. Clinical Efficacy: Clinical studies have demonstrated that Teduglutide can reduce the volume and frequency of parenteral nutrition required, thereby supporting nutritional autonomy in patients with SBS. Long-term Management: It is used as a long-term treatment to sustain intestinal adaptation and improve nutritional outcomes, offering a more sustainable approach compared to solely relying on parenteral nutrition. Teduglutide's role in promoting intestinal function and reducing the burden of parenteral nutrition underscores its significance in managing short bowel syndrome and improving the overall health outcomes of affected individuals.